Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Melhorando a mobilidade após revascularização na doença arterial periférica (IMPACT PAD)

30 de setembro de 2026 atualizado por: Mary McDermott, Northwestern University

Melhorando a mobilidade após revasCularização na doença arterial periférica: o ensaio IMPACT PAD

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.

In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.

Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.

Tipo de estudo

Intervencional

Inscrição (Estimado)

386

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Arizona
      • Tucson, Arizona, Estados Unidos, 85724
        • Recrutamento
        • University of Arizona
        • Contato:
          • Wei Zhou, MD
    • California
      • Downey, California, Estados Unidos, 90242
        • Recrutamento
        • Rancho Research Institute
        • Contato:
          • Tze-Woei Tan, MD
    • Florida
      • Tampa, Florida, Estados Unidos, 33606
        • Recrutamento
        • University of South Florida
        • Contato:
          • Ulka Sachdev, MD
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30307
        • Recrutamento
        • Emory University School of Medicine
        • Contato:
          • Olamide Alabi, MD
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago
        • Contato:
          • Tamar Polonsky, MD
          • Número de telefone: 773-702-6153
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern University Feinberg School of Medicine
        • Investigador principal:
          • Mary M McDermott, MD
        • Contato:
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Recrutamento
        • Henry Ford Health
        • Contato:
          • Jonathan Ehrman, PhD
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03766
        • Recrutamento
        • Dartmouth Hitchcock Medical Center
        • Contato:
          • Philip P Goodney, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.

Exclusion Criteria:

  1. History of leg amputation, not including toe and partial foot amputation
  2. Active gangrene
  3. Active limb threatening ischemia
  4. Already exercising at a level consistent with exercise intervention, using investigator discretion.
  5. Unstable angina
  6. Unwilling to drink study beverages
  7. Unwilling to adhere to the interventions and complete follow-up testing
  8. Currently taking sildenafil, tadalafil, or related drugs.
  9. Unwilling to accept randomization into either group (home-based exercise or attention control)
  10. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
  11. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
  12. Baseline blood pressure <100/45.
  13. Wheelchair confinement or requiring a walker to ambulate
  14. Walking is limited by a condition other than PAD
  15. Current foot ulcer
  16. Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
  17. Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
  18. Allergy to beetroot juice
  19. Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
  20. Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
  21. Visual impairment that limits walking ability.
  22. Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
  23. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  24. Planning to begin a supervised treadmill exercise program in the next 12 months.
  25. Heart attack or stroke in previous three months prior to baseline testing.
  26. An eGFR value <30 or potassium >5.0.
  27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Home based exercise + nitrate rich beetroot juice

This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Comparador de Placebo: Home-based exercise + placebo

This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Experimental: Attention control + nitrate-rich beetroot juice

This group will be participating in attention control and drinking nitrate rich beetroot juice for six months.

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Comparador de Placebo: Attention control + placebo

This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months.

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Six-Minute Walk Distance 6-month change
Prazo: Baseline to 6-month follow-up

Distance walked in six minutes

Baseline to 6-month follow-up

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Prazo: Baseline to 6-month follow-up.

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 6-month follow-up.
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Prazo: Baseline to 12-month follow-up

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 12-month follow-up
PROMIS Mobility Questionnaire Score 6-month change
Prazo: Baseline to 6-month follow-up

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 6-month follow-up
PROMIS Mobility Questionnaire Score 12-month change
Prazo: Baseline to 12-month follow-up.

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 12-month follow-up.
Prevention of Hemodynamic Failure of The Revascularized Vessel
Prazo: Baseline to 12 month follow-up

Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel.

Baseline to 12 month follow-up
Change in 6-minute walk distance
Prazo: 12 month follow-up

Change in 6-minute walk distance between baseline and 12-month follow-up

12 month follow-up

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Six-Minute Walk Distance
Prazo: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink

Change in six-minute walk distance 24 hours after the final study beverage

Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
Plasma Nitrite Levels
Prazo: Baseline to 6-month follow-up

Change in plasma nitrite levels in the blood at 6-month follow-up

Baseline to 6-month follow-up
BH4/BH2 6-month change
Prazo: Baseline to 6-month follow-up

Change in BH4/BH2 ratio

Baseline to 6-month follow-up
Progression of PAD
Prazo: Baseline to 12-month follow-up

Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up.

Baseline to 12-month follow-up

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de agosto de 2025

Conclusão Primária (Estimado)

1 de fevereiro de 2032

Conclusão do estudo (Estimado)

1 de agosto de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

8 de novembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2024

Primeira postagem (Real)

13 de novembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • STU00222333

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Prazo de Compartilhamento de IPD

Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.

Critérios de acesso de compartilhamento IPD

Per BioLINCC

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .